402 related articles for article (PubMed ID: 29523108)
21. Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system.
Winer RL; Tiro JA; Miglioretti DL; Thayer C; Beatty T; Lin J; Gao H; Kimbel K; Buist DSM
Contemp Clin Trials; 2018 Jan; 64():77-87. PubMed ID: 29113956
[TBL] [Abstract][Full Text] [Related]
22. Equal prevalence of severe cervical dysplasia by HPV self-sampling and by midwife-collected samples for primary HPV screening: a randomised controlled trial.
Hellsten C; Ernstson A; Bodelsson G; Forslund O; Borgfeldt C
Eur J Cancer Prev; 2021 Jul; 30(4):334-340. PubMed ID: 34010238
[TBL] [Abstract][Full Text] [Related]
23. Mailed HPV self-sampling for cervical cancer screening among underserved minority women: study protocol for a randomized controlled trial.
Kobetz E; Seay J; Amofah A; Pierre L; Bispo JB; Trevil D; Gonzalez M; Poitevien M; Koru-Sengul T; Carrasquillo O
Trials; 2017 Jan; 18(1):19. PubMed ID: 28086983
[TBL] [Abstract][Full Text] [Related]
24. Participation in Cervical Screening by Self-collection, Pap, or a Choice of Either in Brazil.
Castle PE; Silva VRS; Consolaro MEL; Kienen N; Bittencourt L; Pelloso SM; Partridge EE; Pierz A; Dartibale CB; Uchimura NS; Scarinci IC
Cancer Prev Res (Phila); 2019 Mar; 12(3):159-170. PubMed ID: 30651294
[TBL] [Abstract][Full Text] [Related]
25. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening.
Snijders PJ; Verhoef VM; Arbyn M; Ogilvie G; Minozzi S; Banzi R; van Kemenade FJ; Heideman DA; Meijer CJ
Int J Cancer; 2013 May; 132(10):2223-36. PubMed ID: 22907569
[TBL] [Abstract][Full Text] [Related]
26. A Home-Mailed Versus General Practitioner-Delivered Vaginal Self-Sampling Kit for Cervical Cancer Screening: A Cluster Randomized Controlled Trial with a Cost-Effectiveness Analysis.
Boyard J; Caille A; Brunet-Houdard S; Sengchanh-Vidal S; Giraudeau B; Marret H; Rolland-Lozachmeur G; Rusch E; Gaudy-Graffin C; Haguenoer K
J Womens Health (Larchmt); 2022 Oct; 31(10):1472-1480. PubMed ID: 35834620
[No Abstract] [Full Text] [Related]
27. CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: Design, methods and baseline data of 18,471 women.
Morisada T; Teramoto K; Takano H; Sakamoto I; Nishio H; Iwata T; Hashi A; Katoh R; Okamoto A; Sasaki H; Nakatani E; Teramukai S; Aoki D
Cancer Epidemiol; 2017 Oct; 50(Pt A):60-67. PubMed ID: 28818742
[TBL] [Abstract][Full Text] [Related]
28. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women.
Nobbenhuis MA; Helmerhorst TJ; van den Brule AJ; Rozendaal L; Jaspars LH; Voorhorst FJ; Verheijen RH; Meijer CJ
J Clin Pathol; 2002 Jun; 55(6):435-9. PubMed ID: 12037026
[TBL] [Abstract][Full Text] [Related]
29. Value of a catch-up HPV test in women aged 65 and above: A Danish population-based nonrandomized intervention study.
Tranberg M; Petersen LK; Hammer A; Elfström M; Blaakær J; Jørgensen SF; Bennetsen MH; Jensen JS; Andersen B
PLoS Med; 2023 Jul; 20(7):e1004253. PubMed ID: 37410699
[TBL] [Abstract][Full Text] [Related]
30. Effect of Sequential Rounds of Cervical Cancer Screening on Management of HPV-positive Women: A 15-year Population-based Cohort Study from China.
Xu XQ; Rezhake R; Hu SY; Chen F; Zhang X; Pan QJ; Zhang WH; Ma JF; Qiao YL; Zhao FH; Cruickshank M
Cancer Prev Res (Phila); 2021 Mar; 14(3):363-372. PubMed ID: 33303694
[TBL] [Abstract][Full Text] [Related]
31. The cost-effectiveness of opt-in and send-to-all HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: The Equalscreen randomized controlled trial.
Knauss T; Hansen BT; Pedersen K; Aasbø G; Kunst N; Burger EA
Gynecol Oncol; 2023 Jan; 168():39-47. PubMed ID: 36371904
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms.
Lam JU; Rebolj M; Møller Ejegod D; Pedersen H; Rygaard C; Lynge E; Thirstrup Thomsen L; Krüger Kjaer S; Bonde J
Int J Cancer; 2017 May; 140(10):2212-2219. PubMed ID: 28195317
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
[TBL] [Abstract][Full Text] [Related]
34. Comparative Assessment of a Self-sampling Device and Gynecologist Sampling for Cytology and HPV DNA Detection in a Rural and Low Resource Setting: Malaysian Experience.
Latiff LA; Ibrahim Z; Pei CP; Rahman SA; Akhtari-Zavare M
Asian Pac J Cancer Prev; 2015; 16(18):8495-501. PubMed ID: 26745108
[TBL] [Abstract][Full Text] [Related]
35. Assessing the impact of mailing self-sampling kits for human papillomavirus testing to unscreened non-responder women in Manitoba.
Jalili F; O'Conaill C; Templeton K; Lotocki R; Fischer G; Manning L; Cormier K; Decker K
Curr Oncol; 2019 Jun; 26(3):167-172. PubMed ID: 31285661
[TBL] [Abstract][Full Text] [Related]
36. The costs of offering HPV-testing on self-taken samples to non-attendees of cervical screening in Finland.
Virtanen A; Anttila A; Nieminen P
BMC Womens Health; 2015 Nov; 15():99. PubMed ID: 26542953
[TBL] [Abstract][Full Text] [Related]
37. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial.
Broberg G; Gyrd-Hansen D; Miao Jonasson J; Ryd ML; Holtenman M; Milsom I; Strander B
Int J Cancer; 2014 May; 134(9):2223-30. PubMed ID: 24127304
[TBL] [Abstract][Full Text] [Related]
38. Factors associated with low adherence to cervical cancer follow-up retest among HPV+/ cytology negative women: a study in programmatic context in a low-income population in Argentina.
Gago J; Paolino M; Arrossi S
BMC Cancer; 2019 Apr; 19(1):367. PubMed ID: 31014287
[TBL] [Abstract][Full Text] [Related]
39. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
40. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials.
Verdoodt F; Jentschke M; Hillemanns P; Racey CS; Snijders PJ; Arbyn M
Eur J Cancer; 2015 Nov; 51(16):2375-85. PubMed ID: 26296294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
